 |
| Hillary Clinton and Nicolas Sarkozy, March 14, 2011 |
 |
| President Obama and Mark Pekala, June 6, 2009, Paris |
France gets an A+ from the US for its anti consumer intellectual property related policies
September 6, 2011
KEI staff review of Wikileaks cables (/wikileaks)
Feb 28, 2003 | Turkey | Consulate Istanbul | Differences Among U.s. Firms Give Rise To New Association Of Research-based Pharmaceutical Companies
Continue Reading
WTO PUBLIC FORUM 2011
TITLE: Proposal for a WTO Agreement on the Supply of Knowledge as a Public Good
DATE: Wednesday, 21 September 2011
TIME: 16:15-18:15
VENUE: Room E (located on 3rd floor), World Trade Organization
REGISTRATION: Mandatory, please complete the registration form by 14 September 2011.
From KEI staff review of Wikileaks cables (/wikileaks)
This cable signed by US Ambassador to Poland Victor H. Ashe provides a through and very tough critique of PhRMA’s submission to the 2009 Special 301 list. Ashe rejects every one of PhRMA’s main points, and explains why continually putting Poland on the Special 301 list is counter productive.
The proposal for a WIPO treaty for persons who are blind or have other disabilities moved forward at the last SCCR meeting in June 2011, when a wide collection of high income and Latin American countries endorsed a joint paper that could serve as a basis for a diplomatic conference. The fact that Brazil, the US and the EU were among the countries endorsing the paper was very significant.
This July 9, 2008 cable concerns the collaboration between the US government and the pharmaceutical industry to lobby Finland on the pricing of pharmaceutical drugs. The cable was written by Michael A Butler, then the Deputy Chief of Mission in Helsinki, and is worth a read. Among other things, the cable says :
 |
 |
| Ambassador Clifford Sobel (photo from Wikimedia) |
Wikileaks has published 28 cables, dated July 13, 2004 to February 9, 2010, from the US Embassy in Wellington, New Zealand that mention pharmaceuticals (See list here: /node/1231)
One of the cables discusses in detail the efforts of the New Zealand government to prevent pharmaceutical products that are sold in New Zealand from being parallel traded into the U.S. market. There are several interesting points made in the cable. Here are a few highlights: